Status:
UNKNOWN
The Treatment of Lenalidomide in Patients With POEMS Syndrome
Lead Sponsor:
Istituto Clinico Humanitas
Conditions:
POEMS Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Lenalidomide is a immunomodulatory drug derived from thalidomide, without neurotoxicity. Lenalidomide blocks the increased secretion of interleukin-6, tumor necrosis factor alpha and vascular endothel...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of POEMS syndrome based on published diagnostic criteria
Exclusion
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2011
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00971685
Start Date
July 1 2009
End Date
July 1 2011
Last Update
September 2 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinco Humanitas
Rozzano, Milano, Italy, 20089